Signature Care Blemish and Blackhead Control

Description

The product is identified by the SPL Code 34089-3 and is designated as SY70112A3. It is available in a media type of image/jpeg, with a reference file named SY70112A3.jpg.

Uses and Indications

This drug is indicated for the treatment of acne. There are no teratogenic or nonteratogenic effects associated with its use as mentioned in the available data.

Dosage and Administration

The affected area should be covered with a thin layer of the medication and rinsed thoroughly. Initial application should be limited to once daily to minimize the risk of excessive skin drying. Based on the patient's response, the frequency may be gradually increased to two or three times daily, as needed or as directed by a healthcare professional.

In cases where bothersome dryness or peeling occurs, it is advisable to reduce the application frequency to once daily or every other day. Careful monitoring of the skin's response is recommended to ensure optimal treatment outcomes while minimizing adverse effects.

Contraindications

Use of this product is contraindicated in individuals with a history of eye contact. In the event of contact with the eyes, it is imperative to flush thoroughly with water. No other contraindications have been identified.

Warnings and Precautions

For external use only. Healthcare professionals should advise patients to adhere strictly to this guideline to prevent unintended systemic exposure.

Skin irritation and dryness may be exacerbated when used concurrently with other topical acne medications. It is recommended that only one topical acne treatment be utilized at a time to minimize the risk of irritation. Patients should be monitored for signs of skin irritation, and if such symptoms arise, they should discontinue use and consult their healthcare provider.

Contact with the eyes should be strictly avoided. In the event of accidental contact, patients should be instructed to flush the eyes thoroughly with water to mitigate potential adverse effects.

In cases of ingestion, immediate medical assistance should be sought, or the patient should contact a Poison Control Center without delay. Prompt action is critical to ensure patient safety.

Patients are encouraged to communicate any concerns or adverse reactions to their healthcare provider, although no specific instructions for discontinuation have been provided in the current guidelines. Regular follow-up may be beneficial to assess the patient's response to treatment and to manage any potential side effects effectively.

Side Effects

For external use only. No specific adverse reactions or side effects have been identified in clinical trials or postmarketing experiences. Patients should be advised to use the product as directed and to report any unexpected reactions to their healthcare provider.

Drug Interactions

The concurrent use of multiple topical acne medications may increase the risk of skin irritation and dryness. To mitigate this risk, it is advised that only one topical acne medication be used at a time. If irritation occurs, discontinuation of additional topical agents is recommended to allow the skin to recover. Monitoring for signs of irritation is essential to ensure patient comfort and treatment efficacy.

Packaging & NDC

Below are the non-prescription pack sizes of Signature Care Blemish and Blackhead Control (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be monitored closely when using this medication. It is essential to keep the product out of reach of children. In the event of accidental ingestion, immediate medical assistance or contact with a Poison Control Center is advised.

For topical application, it is recommended to initiate treatment with one application daily. Depending on the patient's response and as directed by a healthcare professional, the frequency may be gradually increased to two or three times daily. Care should be taken to observe for excessive drying of the skin; if bothersome dryness or peeling occurs, the application frequency should be reduced to once a day or every other day.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

There is currently no information available regarding the use of SIGNATURE CARE BLEMISH AND BLACKHEAD CONTROL (salicylic acid emulsion) during pregnancy. This includes a lack of data on safety concerns, dosage modifications, or any special precautions that should be taken when considering its use in pregnant patients. Healthcare professionals are advised to weigh the potential risks and benefits when prescribing this product to women of childbearing potential. Given the absence of specific information, caution is recommended in the use of this product during pregnancy.

Lactation

There are no specific statements regarding the use of this medication in nursing mothers or its effects during lactation. Additionally, there is no available data on the excretion of this medication in breast milk or its potential effects on breastfed infants. Healthcare professionals should consider the absence of information when advising lactating mothers about the use of this medication.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available data regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to patients with reduced kidney function, as the lack of information necessitates careful clinical judgment and monitoring.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution when administering the medication. It is essential to monitor patients closely for any signs of adverse effects or symptoms that may arise from excessive dosing.

In the event of suspected overdosage, immediate medical attention should be sought. Healthcare providers should implement supportive measures as necessary, which may include symptomatic treatment and monitoring of vital signs.

Due to the lack of detailed overdosage information, it is recommended that healthcare professionals refer to established clinical guidelines and protocols for managing overdose situations relevant to the specific medication in question. Additionally, contacting a poison control center may provide further guidance on appropriate management strategies.

Continued vigilance and patient assessment are crucial in mitigating potential risks associated with overdosage.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in question. Further studies may be necessary to elucidate these aspects of nonclinical toxicology.

Postmarketing Experience

No postmarketing experience details are provided in the insert.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the medication is swallowed.

It is important to inform patients that the use of this medication in conjunction with other topical acne treatments may increase the likelihood of skin irritation and dryness. Therefore, if patients experience irritation, they should be instructed to use only one topical acne medication at a time to minimize adverse effects.

Patients should also be cautioned to avoid contact with the eyes. In the event of accidental contact, they should be directed to flush the eyes thoroughly with water to reduce the risk of irritation or injury.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at room temperature to maintain its integrity and efficacy. No special handling requirements are necessary beyond standard storage practices.

Additional Clinical Information

The medication is administered topically, requiring patients to cover the entire affected area with a thin layer and rinse thoroughly one to three times daily. To minimize the risk of excessive skin drying, it is recommended to start with one application daily, gradually increasing to two or three times daily as needed or directed by a clinician. Should patients experience bothersome dryness or peeling, they should reduce the frequency of application to once a day or every other day.

No additional information is available regarding laboratory tests, abuse potential, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Signature Care Blemish and Blackhead Control, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)